Chemotherapy-Induced Nausea and Vomiting (CINV) Clinical Trial
Official title:
MK0869 and MK0517 Time-on-Target PET Study
This study will evaluate if the mean value of brain neurokinin 1 (NK1)-receptor occupancy of participants treated with aprepitant is similar to that of participants treated with fosaprepitant at certain timepoints.
The third arm of the study (Aprepitant 250 mg) will only be conducted if the real-time assessment of the NK1-receptor occupancy data between fosaprepitant 150 mg & aprepitant 165 mg reveals that the primary hypothesis will not be supported. ;
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01594749 -
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)
|
Phase 3 | |
| Not yet recruiting |
NCT04912271 -
Granisetron Transdermal Patch for Prophylaxis of Delayed CINV
|
Phase 3 | |
| Active, not recruiting |
NCT05434663 -
Safety Study of Repeat Doses of SUSTOL in Adults
|
Phase 4 | |
| Recruiting |
NCT04472143 -
Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents
|
Phase 2 | |
| Completed |
NCT00619359 -
Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)
|
Phase 3 | |
| Completed |
NCT03204279 -
PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting
|
Phase 2 | |
| Completed |
NCT00952341 -
Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)
|
Phase 3 |